Last reviewed 2026-04-20 · How we verify

Elocta (EFMOROCTOCOG ALFA)

At a glance

Approved indications

• Hereditary factor VIII deficiency disease

Common side effects

• Factor VIII inhibition
• Device-related thrombosis
• Rash papular
• Arthralgia
• Malaise
• Myalgia
• Headache
• Rash
• Dizziness
• Dysgeusia
• Bradycardia
• Hypertension

Serious adverse events

• Myocardial infarction
• Angiopathy

Key clinical trials

• A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
• POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies (PHASE4)
• An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa (PHASE4)
• Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
• A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
• Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (PHASE4)
• Health Related Quality of Life of Youth and Young Adults With Haemophilia A (PHASE4)
• The Hemophilia Inhibitor Prevention Trial (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Elocta CI brief — competitive landscape report
• Elocta updates RSS · CI watch RSS
• Swedish Orphan Biovitrum AB portfolio CI